« Back
Home /
Pamidronate (disodium)

Pamidronate (disodium)

Item no.	HY-B0012A-25mg
Manufacturer	MedChem Express
CASRN	57248-88-1
Amount	25 mg
Quantity options	100 mg 10 mg 1 ea 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lymphatic System Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Ashton JA, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cellsfrom dogs. Am J Vet Res. 2005 May;66(5):885-91.\|[2]Xu Y, et al. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Mar 22.\|[3]Lv Y, et al. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord. 2014 Nov 6;15:370.\|[4]Kovacs R, et al. The synthesis of pamidronic derivatives in different solvents: An optimization and a mechanistic study[J]. Heteroatom Chemistry, 2014, 25(3): 186-193.
Smiles	OP(C(O)(P(O)(O[Na])=O)CCN)(O[Na])=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CGP 23339A
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	RANKL/RANK ; Toll-like Receptor (TLR); Wnt; β-catenin
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	279.03
Product Description	Pamidronate disodium (CGP 23339A), the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma[1][2][3][4].
Manufacturer - Research Area	Cancer; Metabolic Disease; Inflammation/Immunology
Solubility	H2O: 50 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Immunology/Inflammation; NF-κB; Stem Cell/Wnt
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B0012A-25mg-safety-datasheet.pdf